CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will participate in two investor conferences.
SunTrust Rare Disease Day - Dr. Fambrough will participate in the
SunTrust Robinson Humphrey 2018 Orphan Drug Day on Tuesday, February
13, 2018, at the JW Marriott Essex House in New York.
Leerink Global Healthcare Conference - Dr. Fambrough will participate
in a fireside chat on Wednesday, February 14, 2018 at 1:00 p.m. ET at
the Lotte New York Palace in New York.
A live webcast of the fireside chat at the Leerink Global Healthcare
Conference can be accessed on the Investors & Media section on the
Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative, subcutaneously delivered
RNAi-based therapeutics for diseases involving the liver, including rare
diseases, chronic liver diseases, cardiovascular diseases, and viral
infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi
technology platform to build a broad pipeline in these core therapeutic
areas, focusing on target genes where connections between target gene
and diseases are well understood and documented. Dicerna intends to
discover, develop and commercialize novel therapeutics either on its own
or in collaboration with pharmaceutical partners. For more information,
please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180206005171/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media